Sire	PATE	NTS AND OTHER I MATION DISCLOS	ATTY. DOC T NO. 30727.0013.CIP1 APPLICANT: METABASIS THERA			SERIAL NO. 09/518,501				
10H 1 1 20	พี่สุด	se several sheets i	f necessary)	#	FILING DATE March 5, 19	:		GROUP 1614		
2014	5				March J, 19	99	\dashv	1014		
TA TRADE	MARK									
		·	U.S. P	ATENT DOCU	IMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		IAME	CL	 ASS	SUB		FILING DATE
Thi	AA	3,018,302	01.23.62	Bielefeld, e	t al.				_	DAIL
	AB	5,157,027	10/20 92	Biller, et al.					\top	
W	AC	5,658,889	8/19/97	Gruber, et a	nl.					·
7						_ L		<u></u>	<u> </u>	
			FOREIGN	PATENT DO	CUMENTS	· ·			- 1	
EXAMINER						1		SUB	T	RANSLATIO
INITIAL		DOCUMENT NUMBER	DATE	COI	JNTRY	CLA	SS	CLASS	_	ES NO
4	AD	0 002 062 A	30.05.79	EP (Abstract)					
	AE	0 072 531 A	23,02.83	EP (Atstract)	- -			_	
_	AF	0 158 057 A	16.10.85	EP (Abstract	<u> </u>					
	AG	0 180 276	28.12.88	EP						
	АН	0 261 283	22.09.86	EP						
	Al	0 161 955 A	21.11.85	EPO						
	AJ	0 338 372 A	25.10.89	EPO						
	AK	0 353 692 A	07.02.90	EPO			7			
	AL	0 481 214 A	22.04.92	EPO						
	AM	492 738 A	30.06.70	СН			\dashv	+>	1	_
IV /	AN	16 93 219,A	7			++	-+		+	

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PT	0-144	9			ATTY, DOC	NO.	SERIAL N	10.	
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S					30727.0013.CIP1 09/518,501				
	INFORMATION DISCLOSURE STATEMENT					rued v	DEUTION	INO	
PI	E JC:				METABASIS 1 FILING DATE:	MERA	GROUP:	, INC.	
<u>\o`</u>	(E	اغو several sheets ا	if necessary)		March 5, 1999)	1614		
	1.100	PERIO					· · · · · · · · · · · · · · · · · · ·		
HUL	ند	<i>Ĕ</i>)	FOREIGN	PATENT DO	CUMENTS				
EXAMINER	8 RADE]	SUB	TRANSI	ATION
INITIAL		DOCUMENT NUMBER	DATE		UNTRY	CLASS	CLASS	YES	NO
X	AO	35 12 781 A1	10.04.85	U.S. Patent	glish language No. 4,952,740)				
	AP	96/01267 A	18.01.96	wo					
	AQ	97/03679 A	06.02.97	wo					
<u> </u>	AR	98/09668 A	12.03.98	wo	/_				
<u>- - </u>	AS	98/39342	11.09.98	wo					
	AT	98/39343	11.09.98	wo	······································				
	AU	98/39344	11.09.98	wo					
								-	
	ОТН	ER DOCUMENTS	S (Includin	g Author, Til	ile, Date, Perti	nent F	Pages, etc	:.)	
gr	AV	"Patent Abstrac (Yamishata Koji	ts of Japan," i; Nippon So	' Vol. 1998, No da Co. Ltd), 1	o. 1, 30 January 6 September 19	1998 8 97	& JP 09 24	1284 A	
	AW	DeLombaert, et a New Generati Chem. 37: 498-	al., "N-Phoson of Neutra	phonomethyl	Dipeptides and	Their F	Phosphona) Inhibitors	te Prod s, <u>J. Me</u>	rugs, d.
		Edmunson, et a Assignments in Structure of <i>cis</i> -	the 4-Pheny	/l-1,3,2λ5-diox	aphosphorinane	Series	s. X-Rav M	lolecula	r l
1	AX_	Res. Synop., 5:	<u>122-123 (19</u>	89)					
	AY	Farquhar, et al., fluorouridine: a r (FDUMP)'" J. Mo	membrane-p	ermeating pro	drug of 5-fluoro	in an - -2'-deo	2-y]!-2' - de xyuridylic	oxy-5- acid	
4	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> 72(3): 3/24 (1983)								
	cel de licales								
EXAMINER:	eg T	\bigcap	(1 V)	DATE	CONSIDERED:	1/	/		
Examiner	\mathcal{K}	mig Il	Myla			19/1	7		
EXAMINI line through	EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw ine through citation if not in conformance and not considered. Include a copy of this form with next								

communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT ATTY. DOC T NO. 30727.0013.CIP1 O9/518,501 APPLICANT: METABASIS THERAPEUTICS, INC.

(Use several sheets if necessary)

FILING DATE: GROUP:
March 5, 1999 1614

204	6/	
TA TRAD	HTCH	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
gen	ВА	Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2-oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2-dioxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. ©hem. 28: 1358-1361 (1985)
	ВВ	Farquhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5- Pluoro-2'-deoxyuridine 5'-Phosphate," <u>J. Med. Chem.</u> 26: 1153-1158 (1983)
	вс	Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'- Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," <u>Biochem. Pharmac.</u> 38: 3193-3198 (1989)
	BD	Hillers, et al., "Analogs of pyrimidine mono-and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864a
	BE	Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984)
	BF	Kryuchkov, et al. Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987)
	BG	Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," <u>J. Antimicrob. Chemotherap.</u> 14: 93-99 (1984)
	вн	Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenyl ketophos phamide" and Similar Compounds Related to the Cyclophosphamide Metabolyte Aldophosphamide," J. Med Chem. 29, 716-727 (1986)
·	BI	Meier, et al., "Cyclic Saligenyl Phosphotreisters of 2', 3'-Dideoxy-2', 3'-didehydrothymidine (d4T) – A New Pro-Nucleotide Approach," <u>Bioorg. Med. Chem.</u> <u>Lett.</u> 7: 99-104 (1977)
	ВЈ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thioinosinic Acid," <u>J. Med. Chem.</u> 22: 811-815 (1979)
	BK	Neidlein, et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester Amides," Neterocycles 35: 1185-1203 (1993)

EXAMINER:

DATE CONSIDERED:

CONSIDERED:

DATE C

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT OPE CO. (Use several sheets if necessary) ATTY. DOC T NO. 30727.0013.CIP1 09/518,501 APPLICANT: METABASIS THERAPEUTICS, INC. FILING DATE: March 5, 1999 1614

<i>\</i>	111	윤	
	•	STH	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
4	The TRAD	BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", <u>Zh. Obshch. Khim., Vol. 49, No. 1, 1979, Pages 64-74 (and English version as translated in corresponding English language publication)</u>
		вм	Nifantyev, et al.,"Synthesis and Structure of Some Stable Phospholane- Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)
		BN	Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic</u> Chemistry of the USSR (English Translation 13:1489-1492 (1977))
•		ВО	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholipe" <u>Journal of Organic Chemistry of the USSR (English Translation</u> 17:1156-1165 (1981)
		BP	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S24 (1993)
		BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem. Acad. Sin. 41: 9-16 (1994)
		BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> 37: 1957-1864 (1994)
Ĺ.,		ВS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)
	*	ВТ	Zon, ét al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)
•	-	J	H dofrection

EXAMINER:	DATE CONSIDERED:
Example WWW MILES	1/9/02
EXAMINER: Initial if reference is considered, whether or line through citation if not in conformance and not consider	r not citation is in conformance with MPEP 609; Drawered. Include a copy of this form with next

communication to applicant

•								
FORM PTO-1449	ATTY. DOCKS NO. 30727.001 SIP1		SERIAL NO. 09/518,501					
	NTS AND OTHER IT MATION DISCLOSU			APPLICANT: METABASIS THERAPEUTICS, INC.				
<i>∯U</i> (∪	se several sheets if	necessary)		FILING DATE: GROUP: March 5, 1999				
	OIPE	· _ ·				_,¿C	<u> </u>	
7	FEB 2 5 2007 55					MAR	VAN	
PAR		U.S. PA	TENT DOC	UMENTS	"ECH	CENT	2002	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SIGN (CLASS OF	FILING DATE	
TCM AA	3,018,302	01/23/62	Bielefeld,	et al.	260	46	2300	
JUM AB	5,157,027	10/20/92	Biller, et al	•	514	167		
MAC	5,658,889	8/19/97	Gruber, et	al.	514	43		

FOREIGN PATENT DOCUMENTS									
EXAMINER						SUB		LATION	
INITIAL	ļ	DOCUMENT NUMBER	DATE	COUNTRY	CLA	SS_	CLASS	YES	NO_
1CM	AD	0 002 062 A1	30.05.79	EP (and English language -Abstract)	1				
TU	AE_	0 072 531 A1	23.02.83	EP (and English language -Abstract)					
Or	AF	0 158 057 A	16.10.85	EP (U.K. English language translation)					
	AG	0 180 276 A1	28.12.88	EP					
	AH	0 261 283 A1	22.09.86	EP					
	Al	0 161 955 A1	21.11.85	EPO					
	AJ	0 338 372 A2	25.10.89	EPO				ļ	
	AK	0 353 692 A2	07.02.90	EPO					
	AL	0 481 214 B1	22.04.92	EPO					
	AM	492 738	30.06.70	CH (and English language Abstract)					
$\overline{\mathbb{V}}$	AN	987,378	17.09.70	UK					

EXAMÍNER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered,	whether or not citation is in conformance with MPEP 609; Draw not considered. Include a copy of this form with next
communication to applicant	

FCRM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets of thecessary)

ATTY. DOCKET NO. 30727.001 IP1 APPLICANT:

SERIAL NO. 09/518,501

METABASIS THERAPEUTICS, INC.

FILING DATE: March 5, 1999 **GROUP:** 1614

		PAR	FOREISN	PATENT DOCUMENTS			MA	R.	VE
EXAMINER INITIAL		DOCUMENT NUMBER	MARY PERIO	COUNTRY	CLA	ss FC	SUB LASSA/	YES YES	ATION OIKO
/m	AO	35 12 781 A1	10.04.85	DE (and English language U.S. Patent No. 4,952,740)			'''	**************************************	2900
	AP	96/01267	18.01.96	wo					
	AQ	97/03679	06.02.97	wo					
	AR	98/09668	12.03.98	wo					
	AS	98/39342	11.09.98	wo					
7	AT	98/39343	11.09.98	wo					
	AU	98/39344	11.09.98	wo					

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
10	h AV	"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09241284 A (Yamishata Koji, et al.; Nippon Soda Co. Ltd), 16 September 1997							
	AW	DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endoprptidase (NEP, EC 3.4.24.11) Inhibitors, <u>J. Med. Chem.</u> 37: 498-511 (1994)							
	AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of <i>cis</i> -2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," <u>J. Chem. Res. Synop.</u> , 5: 122-123 (1989)							
	AY	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-y]!-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)" J. Med. Chem. 38:488-495 (1995)							
V	AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> 72(3): 324-325 (1983)							

EXAMINER: Examiner	Barres CIM CS	19	DATE CONSIDERED:	glor
	ion if not in conformance an			rmance with MPEP 609; Draw this form with next

FCRM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICAN INFORMATION DISCLOSURE STATEMENT 5 2002

ATTY. DOCKST NO.

SERIAL NO.

PATENTS AND OTHER ITEMS FOR APPLICANT'S
NFORMATION DISCLOSURE STATEMENT 5 2007 STATEMENT 5 oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2-M dioxazaphosphorinan-2-vI)-ß-D-arabinosvI]adenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. Chem. 28: 1358-1361 BA (1985)Farguhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem. 26: 1153-1158 (1983) BB Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'-Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," <u>Biochem. Pharmac.</u> 38: 3193-3198 (1989) BC Hillers, et al., "Analogs of pyrimidinemono-and polynucleotides, IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski BD Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864a/u. Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984) BE BF Kryuchkov, et al., Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987) Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection." J. Antimicrob. Chemotherap, 14: 93-99 BG (1984)Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues, 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenyl ketophos phamide" and Similar Compounds Related to the Cyclophosphamide Metabolyte Aldophosphamide," J. Med Chem. 29, 716-727 (1986) BH Meier, et al., "Cyclic Saligenyl Phosphotreisters of 2', 3'-Dideoxy-2', 3'didehydrothymidine (d4T) - A New Pro-Nucleotide Approach." Bioorg. Med. Chem. BI Lett. 7: 99-104 (1997) Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thioinosinic Acid," J. Med. Chem. 22: 811-815 (1979) BJ Neidlein, et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester BK Amides," Heterocycles 35: 1185-1203 (1993)

EXAMINER: Examiner	Manus Mill.	DATE CONSIDERED:						
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next								
communication		••						

FORM PTO-1449

ATTY. DOCKET NO. 30727.001

SERIAL NO. 09/518,501

APPLICANT:

METABASIS THERAPEUTIO

1614

(Use several sheets if necessary)

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANTS

INFORMATION DISCLOSURE STATEMEND

FEB 2 5 2002 2

FILING DATE: March 5, 1999

	4. OII O,	1000		_KLA
			70	77
			<i>-1₽</i> ~,	
_	Data	Dortinent	Dagar.	N.

		OTH	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
1	M	BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", Zh. Obshch. Khim., Vol. 49, 1979, Pages 53-61.
		ВМ	Nifantyev, et al.,"Synthesis and Structure of Some Stable Phospholane- Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)
		BN	Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic</u> Chemistry of the USSR (English Translation 13:1489-1492 (1977))
		ВО	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" <u>Journal of Organic Chemistry of the USSR (English Translation</u> 17:1156-1165 (1981)
		вР	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S-294 (1993)
		BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," <u>Bull. Inst. Chem. Acad. Sin</u> , 41: 9-16 (1994)
		BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and <i>in Vitro</i> Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> 37: 1857-1864 (1994)
	/	BS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)
		вт	Zon, et al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)

DATE CONSIDERED: EXAMINER:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

Please type a plus sign (+) inside this box

FEB 2 5 2002

FEB 2 5 JULE OF IS Patent and Trademark Office: (2) resons are required to respond to a collection of information unless?

PTO/SB/08A (08-00) ough 10/31/2002. OMB 0851-0031 contains a valid OMB control number

		e for form 1441		126	.F/		tion unless contains a valid OM	<i>∽</i> ∧\
			DISCI	OSLIB FINANCE	Applicat	ion Number	09/518,501	
				OSURE	Filing D		March 3, 2000	
S	TATE	EMENT B	3Y APP	PLICANT	First Na	med Inventor	Erion	- Ma
_	• • • • •				Group A		1624	W PO V
		fuse as man	ıv sheets a	s necessary)	Examine		T. McKenzie	
		1000 00	.,				000707 0043 OID4	
Sheet		1	of	2	Attorney	Docket Number	030727.0013.CIP1	
heet			of	2	Attorney	Docket Number	030727.0013.CIP1	1800%
heet		1] of	U.S. PATE		MENTS	Draw Children	18003900
•		1 U.S. Pater	of		NT DOCU	MENTS Date of Publication	of Pages, Columns Where Rele	vant
ineet	Cite No.	U.S. Pater		Name of Patentee	NT DOCU	MENTS	of Pages, Column	vani devani
aminer			nt Document	Name of Patentee	NT DOCU	MENTS Date of Publication Cited Document	of Pages, Column Where Refe Passages or R	vani Blovani

				FOREIGN PA	TENT DOCUMEN	TS		
Examiner Initials			Foreign Patent Doc	ument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	1
	Cite No.1	Office ³	Number ⁴	Kind Code' (t)' known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	7
								\perp
		 						┸
								┸
								l

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T²
PW AA		Coppi, et al., "Lewis Acid Mediated Condensation of Alkenols and Aldehydes. A Selective Synthesis of Tetrahydropyrans and Oxepanes," J. Org. Chem., Vol. 53, No. 4, 911-913 (1988)	
AB		Lohr et al., "Targeted chemotherapy by intratumor injection of encapsulated cells engineered to produce CYP2B1, and ifosfamide activating cytochrome P450," Gene Therapy, 5, 1070-1078 (1988).	
AC		Bijsterbosch, et al., "Disposition of the Acyclic Nucleoside Phsophonate (S)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl)Adenine," Antimicrobial Agents and Chemotherapy," Vol. 42, p. 1146-1150 (May 1998).	
V	AD	de Waziers, et al., "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues1," The Journal of Pharmacology and Experimental Therapeutics, Vol. 253, No.1, p. 387-394 (1989).	

Examiner Signature Our McHcs	Date Considered	2/1	2/03	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the emount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to storage the serial house of English Indicated. place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box 3

PTO/SB/08A (08-00) Approved for 250 through 10/31/2002. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no per are required to resigned to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

MADEMA INFORMATION DISCLOSURE

Complete if Known **Application Number** 09/518,501

11	NFOF	RMATION	DISC	CLOSURE	Application Number	09/518,501	— ``	* . *			
		EMENT B			Filing Date	March 5, 1999	1	X			
•	, i /5 [ruriai D	· AP	FLICANI	First Named Inventor	Erion	" PA	トノノ			
		(upp pp			Group Art Unit	1624	. 0	1 1/			
	γ		sneels	as necessary)	Examiner Name	T. McKenzie	KA ()	1. \			
Sheet		2	of	2	Attorney Docket Number	030727.0013.CIP1	VIEW	1000			
		,						~ ~			
							1000	2/20			
				NON PATENT L	TERATURE DOCUMENTS		MAR O	100			
Examiner Initials	Cite No.'	out	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-lasse number(s), publisher, city and/or country where published.								
TU	AE	He, et al., ' Grapefruit	"Inacti Juice	ivation of Cytoch " Chem. Res. To	rome P450 3A4 by Berga exicol, Vol. 11, No. 4, p. 2	mottin a Component of 52-259 (1998).					
8	AF	Jounaidi et Oxazaphos 4391- 4401	sphori	ne-based Cance	er of Human Cytochrome or Gene Therapy," Cancer	P450 Genes for Research, Vol. 58, p.					
							1 1				
.								•			
7											
ļ											
ľ	- 1										
		V					_				
		- ·· 		· .							
ł	ĺ										

			1 /	
Examiner	Dund U	Date	7/17/25	
Coldinatore 1 1	200.0	Considered	W/12/ Os	<u>></u>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

type a plus sign (+) inside this box > 🛨

Sheet

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number Complete If Known

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of

·	Complete ii Kilowii							
Application Number	09/518,501							
Filing Date	March 3, 2000	- O:						
First Named Inventor	Erion et al.). Ç						
Group Art Unit	1624	40						
Examiner Name	McKenzie, T.	667						
Attorney Docket Number	45198.00013.RCE (CIP1)	1/2						

					U.S. PATENT DOCU	MENTS	
		Cite No.'	V.S. Patent I	Document Kind Code ² (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Witters Relevant Passages or Relevant Figures Appear
4	て		6,054,587		Reddy et al.	04/25/00	
7			6,110,903		Kasibhatla et al.	08/29/00	
			6,284,748		Dang et al.	09/04/01	
			6,294,672		Reddy et al.	09/25/01	
\neg			6,312,662		Erion et al.	11/06/01	
			6,399,782		Kasibhatla et al.	06/04/02	
7	$\overline{}$		6,489,476		Dang et al.	12/03/02	

				FOREIGN PA	TENT DOCUMEN	TS		
	a	[Foreign Patent Doc	ument	Name of Patensee or	Date of Publication of	Pages, Columna, Lines,	T
Examiner Initials	Cite No.1	Office ³	Number ⁴	Kind Code' (If known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Te.
	*****							\bot
						<u> </u>		

NON PATENT LITERATURE DOCUMENTS										
Examiner inities	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²							
	•		T							
	l		Ì							
· · · · · · · · · · · · · · · · · · ·			┿							
			l							
		·								

		1		/	
Examiner Signature	10m1	Willer	Date Considered	4/16/	04
	,	7			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Fraw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

of

Sheet

45198.00013.RCE

e type a plus sign (+) inside this box > + Approved for use through 10/31/2002. OMB 0851-0931
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Attorney Docket Number

Substitute for form 1449A/PTO Complete If Kn wn **Application Number** 09/518,501 INFORMATION DISCLOSURE **Filing Date** March 3, 2000 STATEMENT BY APPLICANT First Named Inventor Erion et al. Group Art Unit 1624 (use as many sheets as necessary) **Examiner Name** T. McKenzie

Examiner	Cite	U.S. Patent Document	Name of But store on Assillant	Date of Publication of	Pages, Columns, Lines,
Initiats*	No.	Number . Kind Code . Ut known		Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	 				\rightarrow
	_				
					•

					ATENT DOCUMEN	TS		
Examiner	Cite	l	Foreign Patent Doc	ument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	
Initials	No.1	Office ³	Number ⁴	Kind Code' (If Inown)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Patragus or Relevant Figures Appear	7
							_	1
								\top

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initiats	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(a), volume-issue number(s), publisher, city and/or country where published.	T²
		FARQUHAR et al., "Synthesis and Antitumor Evaluation of Bis[pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	
N	/	LEFEBVRE, et al., Mononucleotide Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3'-Azido-2',3'-dideoxythymidine 5'-Monophosphate," J. Med. Chem., 38:3941-3950 (1995).	

Examiner **Date** Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw the through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁸ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FEB 27

STEND & TH

Approved for use through 10/31/2002. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known **Application Number** 09/518,501 NFORMATION DISCLOSURE March 3, 2000 **Filing Date** STATEMENT BY APPLICANT First Named Inventor Erion et al. Group Art Unit 1624 (use as many sheets as necessary) **Examiner Name** T. McKenzie of **Attorney Docket Number** 032465.00013.RCE (CIP1)

			U.S. PATENT DOCU	MENTS	
Examiner Initials*	Cite No.1	U.S. Patent Document Number Kind Code ³ (# Innown)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Cohurns, Lines, Where Relevant Passages or Relevant Figures Appear
			:		

					TENT DOCUMEN	TS		
Examiner Ci	Cite		Foreign Patent Doc		Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	T
Initials	No.'	Office ³	Number ⁴	Kind Code ((f brown)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	7
· .								1
		<u> </u>						\top

		NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	,
Initiats	No.	serias, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	I,s
81		Beaucage and Iyer, "The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications," <u>Tetrahedron</u> , 49(28):6123-6194 (1993).	
		Borch and Millard, "The Mechanism of Activation of 4-Hydroxycyclophosphamide," J. Med. Chem., 30:427-431 (1987).	
		Cooper et al., "Use of Carbohydrate Derivatives for Studies of Phosphorus Stereo-chemistry. Part II. Synthesis and Configurational Assignments of 1,-3,2-Oxathiaphosphorinan-2-ones and 1,3,2-Dioxaphosphorinan-2-thiones," <u>J. Chem. Soc., Perk. Trans. 1</u> , (10):1049-1052 (1974).	
		De Clercq et al., "A Novel Selective Broad-spectrum Anti-DNA Virus Agent," Nature, 323:464-467 (1986).	-
d		Farquhar et al., "Synthesis and Antitumor Evaluation of Bis[(pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	

Examiner Date Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawdine through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English tanguage Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number

E	700	Substitute for form 144			Co	omplete if Known
	\$\ <u>\</u>	NFORMATIO	N DISC	LOSURF	Application Number	09/518,501
_	-nr 5	STATEMENT	DV AD	DISCANT	Filing Date	March 3, 2000
27	TOW E	SIVICINEM!	DIAF	PLICANI	First Named Inventor	Erion et al.
•	¥	4			Group Art Unit	1624
			ny sheets	as necessary)	Examiner Name	T. McKenzie
1	Astreet	2	of	3	Attorney Docket Number	032465,00013 RCF (CIP1)

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
4		Friis and Bundgaard, "Prodrugs of Phosphates and Phosphonates: Novel Lipophilic a- acyloxyalkyl Ester Derivatives of Phosphate- or Phosphonate Containing Drugs Masking the Negative Charges of these Groups," <u>Euro. J. Pharm. Sci.</u> , 4:49-59 (1996).	
		Harada et al., "Resoluation of 1,3-alkanediols Via Chiral Spiroketals Derived from t- Menthone," <u>Tetrahedron</u> , 28(41):4843-4846 (1987).	-
		Khorana et al., "Cyclic Phosphates. III. Some General Observations on the Formation and Properties of Five-, Six- and Seven-membered Cyclic Phophate Esters," <u>IACS</u> , 79:430-436 (1957).	
		Korba et al., "Liver-targeted Antiviral Nucleosides: Enhanced Antiviral Activity of Phosphatidyl-dideoxyguanosine Versus Dideoxyguanosine in Woodchuck Hepatitis Virus Infection In Vivo," Hepatology, 23(5):958-963 (1996).	
	•	Lefebvre et al., "Mononucleoside Phosphotriester Derivatives with S-acyl-2-thioethyl Bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3'azido-2',3'dideoxythymidine 5'-monophosphate," J. Med. Chem., 38:3941-3950 (1995).	
		Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," J. Med. Chem., 29:716-727 (1986).	
		McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993).	
		Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977).	
		Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," <u>J. Am. Chem. Soc.</u> , 112:6936-3942 (1990).	
7		Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Ketoalkyl Diisopinocampheylborinate Intermediates," Tetrahedron, 38(5):761-764 (1997).	

Examiner Date Considered U.E. Determiner or not offstign is in conformation with MIST and a conformation in the conformation is in conformation in the conformation in

*EXAMINER: Initial if reference considered, whether or no obtation is in conformance with MPEP 609. Down line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FEB 2

Approved for use through 10/31/20/2. OMB 0651-0031
U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete If Known **Application Number** 09/518,501 NFORMATION DISCLOSURE Filing Date March 3, 2000 STATEMENT BY APPLICANT First Named Inventor Erion et al. **Group Art Unit** 1624 (use as many sheets as necessary) **Examiner Name** T. McKenzie **Attorney Docket Number** of 032465.00013.RCE (CIP1)

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, megazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
81		Starrett, Jr. et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," J. Med. Chem., 37:1857-1864 (1994).	
		Thomson et al., "Synthesis, Bioactivation and Anti-HIV Activity of the Bis(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Esters of the 5'-monophosphate of AZT," J. Chem. Soc., Perk. Trans. 1, (11):1239-1245 (1993).	
		Weber and Waxman, "Activation of the Anti-cancer Drug Ifosphamide by Rat Liver Microsomal P450 Enzymes," <u>Biochem. Pharm.</u> , 45(8):1685-1694 (1993).	
		Zon et al., "NMR Spectroscopic Studies of Intermediary Metabolites of Cyclophosphamide. A Comprehensive Kinetic Analysis of the Interconversion of cis- and trans-4-Hydroxycyclophosphamide with Aldophosphamide and Concomitant Partitioning of Aldophosphamide Between Irreversible Fragmentation and Reversible Conjugation Pathways," J. Med. Chem. 27:466-485 (1984).	

Examiner Date Signature Considered whether or not disting in the process with MECO and Date Considered

*EXAMINER: Initial if reference considered, whether or not dilation is in conformance with MPEP 809. Draw the through chatical is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.